Pfizer ramps up stem cell investment

Pharma just loves stem cells these days. The latest evidence of this infatuation with the sector is the May 7 announcement by Pfizer of its further plans for stem cell development within the Pfizer Regenerative Medicine division.

The company had previously announced the establishment of R&D sites at both the Cambridges (UK and MA) and also deals with Cellartis AB and UC San Francisco. The most recent announcement provides details of what Pfizer is aiming to do.